Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06333951 · ClinicalTrials.gov registry record · Phase 1
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
A Phase 1 study of Non-Small Cell Lung Cancer and Thoracic Tumors, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT06333951 is a Phase 1 study of Non-Small Cell Lung Cancer and Thoracic Tumors that is actively recruiting participants, run by Amgen. The registered enrollment target is 500 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06333951, a Phase 1 study of Non-Small Cell Lung Cancer and Thoracic Tumors, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG AMG 193
Study Locations (20)
California
- Comprehensive Blood and Cancer Center - Bakersfield
- City of Hope National Medical Center - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Duarte
- Translational Research in Oncology US Inc, Trio Central Pharmacy - Los Angeles
- University of California Irvine - Orange
- University of California Los Angeles - Santa Monica
New York
- Roswell Park Cancer Institute - Buffalo
- New York University Grossman School of Medicine - New York
- Perlmutter Cancer Center at New York University Langone Hospital----Long Island - New York
- Upstate University Hospital - Syracuse
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Tennessee
- University of Tennessee Medical Center Knoxville - Knoxville
- United States Oncology Regulatory Affairs Corporate Office - Nashville
Colorado
- Rocky Mountain Cancer Centers - Denver
Connecticut
- Eastern Connecticut Hematology and Oncology Associates - Norwich
Minnesota
- HealthPartners Institute - Saint Paul
Missouri
- Saint Lukes Hospital of Kansas City - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-09-17 |
| Est. Completion | 2031-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06333951
The ClinicalTrials.gov registry entry for NCT06333951 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (24% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06333951 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06333951 about?
NCT06333951 is a clinical study titled "AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).". The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic...
What is the current status of trial NCT06333951?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 500 participants. The study started on 2024-09-17. Estimated completion is 2031-10-27.
What conditions does trial NCT06333951 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Thoracic Tumors.
What interventions are being tested in trial NCT06333951?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), AMG 193 (DRUG).
Who is sponsoring clinical trial NCT06333951?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06333951 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.